Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock falls 79.2% from a year ago
Common stock stood at $25K at the end of Q1 FY2026, down 79.2% from a year earlier and up 13.6% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
What to watch
Whether common stock keeps falling in the next quarterly balance sheet after a -79.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 22K USD
- Year-over-year change
- -80.7%
- 4-year CAGR
- +10.0%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22K | -80.7% |
| FY2024 | 2024-12-31 | 114K | +225.7% |
| FY2023 | 2023-12-31 | 35K | +133.3% |
| FY2022 | 2022-12-31 | 15K | +0.0% |
| FY2021 | 2021-12-31 | 15K | — |
Common Stock vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -79.2% is the lowest of 9, against a peer median of +41.0%.
- Common stock amounts to 0.0% of total assets for UNCY, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$138.37M CAD | +1.5% | +6.0% | 597.3% |
| Mar 2026 | $104.89K USD | +216.0% | +34.6% | 0.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $38K USD | +22.6% | +12.1% | 0.0% |
| Mar 2026 | $25K USD | -79.2% | +13.6% | 0.0% | |
| Mar 2026 | $24K USD | +4.3% | +22.7% | 0.0% | |
CBUSCibus, Inc. | Mar 2026 | $13K USD | +44.4% | +150.9% | 0.0% |
| Mar 2026 | $11K USD | +37.5% | +31.0% | 0.0% | |
| Mar 2026 | $7K USD | +75.0% | +32.6% | 0.0% | |
| Mar 2026 | $6K USD | +200.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding UNCY) | — | +41.0% | +31.0% | 0.0% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.